Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Photo: Michel Euler/AP/Ritzau Scanpix

Pfizer is upgrading this year's guidance for sales connected to the company's covid-19 vaccines from USD 26bn to USD 33.5bn, according to the firm's Q2 report.

Looking at this year as a whole, the company now predicts earnings per share of USD 3.95-4.00 compared to a previous estimate of USD 3.55-4-65.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs